[go: up one dir, main page]

AU2001235006A1 - Prophylactic and therapeutic monoclonal antibodies - Google Patents

Prophylactic and therapeutic monoclonal antibodies

Info

Publication number
AU2001235006A1
AU2001235006A1 AU2001235006A AU3500601A AU2001235006A1 AU 2001235006 A1 AU2001235006 A1 AU 2001235006A1 AU 2001235006 A AU2001235006 A AU 2001235006A AU 3500601 A AU3500601 A AU 3500601A AU 2001235006 A1 AU2001235006 A1 AU 2001235006A1
Authority
AU
Australia
Prior art keywords
monoclonal antibodies
prophylactic
therapeutic monoclonal
antibodies
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235006A
Inventor
Jay W. Hooper
Alan L. Schmaljohn
Connie S. Schmaljohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research Institute of Infectious Diseases
Original Assignee
US Army Medical Research Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research Institute of Infectious Diseases filed Critical US Army Medical Research Institute of Infectious Diseases
Publication of AU2001235006A1 publication Critical patent/AU2001235006A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.
AU2001235006A 2000-02-11 2001-02-09 Prophylactic and therapeutic monoclonal antibodies Abandoned AU2001235006A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18206600P 2000-02-11 2000-02-11
US60182066 2000-02-11
PCT/US2001/004520 WO2001058485A2 (en) 2000-02-11 2001-02-09 Prophylactic and therapeutic antibodies against vaccina virus antigens

Publications (1)

Publication Number Publication Date
AU2001235006A1 true AU2001235006A1 (en) 2001-08-20

Family

ID=22666929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235006A Abandoned AU2001235006A1 (en) 2000-02-11 2001-02-09 Prophylactic and therapeutic monoclonal antibodies

Country Status (6)

Country Link
US (2) US6451309B2 (en)
EP (1) EP1309348B1 (en)
AT (1) ATE419872T1 (en)
AU (1) AU2001235006A1 (en)
DE (1) DE60137337D1 (en)
WO (1) WO2001058485A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000275666A (en) * 1999-03-25 2000-10-06 Hitachi Ltd Liquid crystal display
CA2482333A1 (en) * 2002-02-11 2003-08-21 Alexion Pharmaceuticals, Inc. Human antibodies for therapy against vaccinia or smallpox
US6982156B2 (en) * 2002-03-27 2006-01-03 Trustees Of The University Of Pennsylvania Compositions and methods modulating variola and vaccinia virus
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
US20060003316A1 (en) * 2002-07-15 2006-01-05 John Simard Immunogenic compositions derived from poxviruses and methods of using same
WO2004053454A2 (en) * 2002-11-27 2004-06-24 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods for detecting invasion of a cell
US20040185022A1 (en) * 2003-02-19 2004-09-23 Steven Rubin Regimen for acne treatment
AU2004262506A1 (en) * 2003-02-28 2005-02-17 National Institutes Of Health Compositions, methods and kits relating to poxvirus subunit vaccines
JP2007517767A (en) * 2003-03-11 2007-07-05 ダナ ファーバー キャンサー インスティテュート Methods for inhibiting viral pathogenicity
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
EP1781826A4 (en) * 2004-06-12 2009-04-29 Univ Oregon Health & Science COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ORTHOPOXVIRUS
BRPI0512235A (en) * 2004-06-18 2008-02-19 Ambrx Inc antigen-binding polypeptides and their uses
RU2281327C2 (en) * 2004-09-01 2006-08-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" STRAIN OF HYBRID CULTURING Rattus norvegicus 122H9 CELLS WHICH IS PRODUCER OF CROSS-REACTIVE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST PATHOGENIC FOR HUMAN ORTHOPOXVIRUSES
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
US7790182B2 (en) * 2005-09-21 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Protein vaccines against poxviruses
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
WO2008085551A2 (en) * 2006-08-23 2008-07-17 Quercegen Pharma Llc Smallpox monoclonal antibody
WO2008100508A2 (en) 2007-02-12 2008-08-21 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The United States Army Medical Research Institute Of Infectious Diseases Puumala virus full-length m segment-based dna vaccines
WO2009009039A2 (en) * 2007-07-09 2009-01-15 The Usa, As Represented By The Secretary Of The Army, On Behalf Of The United States Army Medical Research Compositions containing full-length l1r nucleic acid and endoplasmic reticulum targeting sequence
RU2342951C1 (en) * 2007-09-12 2009-01-10 Федеральное государственное "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Preparation containing antibody antivariolic from whey of blood of horses, solution for intramuscular introduction
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US9315826B2 (en) 2011-01-31 2016-04-19 The United States of America as rep. by the Sec'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases Nucleic acids containing a synthetic codon-optimized Sin Nombre virus full-length M gene
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
DE102015107577A1 (en) * 2015-05-13 2016-11-17 Osram Opto Semiconductors Gmbh Optoelectronic semiconductor chip
US10381278B2 (en) * 2017-09-14 2019-08-13 Powertech Technology Inc. Testing method of packaging process and packaging structure
IL300836A (en) * 2023-02-21 2024-09-01 State Of Israel Israel Institute For Biological Res Anti–pox viruses antibodies
CN120665190B (en) * 2025-08-21 2025-10-28 中国人民解放军军事科学院军事医学研究院 Anti-orthopoxvirus neutralizing monoclonal antibody B36B9 and application thereof

Also Published As

Publication number Publication date
ATE419872T1 (en) 2009-01-15
US6451309B2 (en) 2002-09-17
WO2001058485A3 (en) 2002-01-10
US20030022226A1 (en) 2003-01-30
WO2001058485A2 (en) 2001-08-16
US20020009447A1 (en) 2002-01-24
EP1309348A2 (en) 2003-05-14
US6620412B2 (en) 2003-09-16
EP1309348B1 (en) 2009-01-07
DE60137337D1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2002078766A3 (en) Combination therapy
PL328858A1 (en) Immunogenous peptides
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AUPP589598A0 (en) Novel peptides
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
YU68602A (en) Monoclonal antibodies to the human ldl receptor, their production and use
WO2003031585A3 (en) Transmembrane serine protease 25
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO1998030190A3 (en) Colon cancer KH-1 and N3 antigens
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2003039455A3 (en) Methods of treating endometreosis
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases